Conservation Tales

Conservation Tales is an interdisciplinary team of students and faculty who work with a variety of external partners to create children's books about wildlife conservation and authentic science practices. In 2021, our external partners include the Ball State Biology Fisheries Research lab, the BSU Field Station and Environmental Education Center, and the Indianapolis Zoo

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

The Frequency and Impact of Self-Imposed Elimination Diets on the Nutritional Status and Clinical Course of Disease in Children with Inflammatory Bowel Disease

Background and aims: From the patients’ perspective, diet has a relevant role in triggering symptoms of inflammatory bowel disease (IBD). There is a lack of prospective studies regarding the diet of children with IBD. The aim of this study was to assess the frequency and impact of self-imposed elimination diets on the nutritional status and clinical course of disease in the pediatric population. Methods: This was a prospective case-control study that included newly diagnosed patients with IBD and healthy controls (age/sex-matched peers and siblings) over a one-year period. The participants were examined in three categories: (1) anthropometric data and nutritional status; (2) dietary intake, as obtained by a Food Frequency Questionnaire (FFQ); and (3) dietary beliefs and elimination diets, as obtained by a structured questionnaire. Results: Overall, one-hundred and thirty-seven participants were included (twenty-eight with Crohn’s disease, sixteen with ulcerative colitis, three with IBD-unclassified, and seventy healthy controls). Only 15% of patients followed the self-imposed elimination diet upon the diagnosis, which increased to 47.6% by the end of the follow-up. The elimination diet did not influence the nutritional status and quality of the diet. Self-imposed elimination diets were not a risk factor for disease relapse. Most of the patients received nutritional counseling during the follow-up. Conclusions: The number of patients following self-imposed elimination diets had increased during the disease course but with no influence on nutritional status or relapse risk

Building Better Neighborhoods Design

The City of Muncie has diverse communities with friendly people, an interesting past, and outstanding cultural amenities that make it a desired place to live, do business, and visit. Until Spring 2019, a lot of the neighborhoods in Muncie were lacking proper visual identification. A strong visual identity was needed to elevate the image of the neighborhood as well as provide a sense of pride among the residents. In partnership with Building Better Neighborhoods and Muncie Action Plan, we worked with a core group of committee members from various Muncie Neighborhoods to develop their visual identity. Check out the other neighborhood identities at the Studio 165+ website: www.studio165plus.com/bb

Conservation Tales - 2022 Central America Series

The Conservation Tales project is finishing work on two new books for this series of children's books. The books will feature Sloths and Macaws, and will make up the new "Central America Series." The set will be published in May 2022. Conservation Tales is an interdisciplinary team of students and faculty who work with a variety of external partners to create children's books about wildlife conservation and authentic science practices. In 2022, our external partners include The Sloth Institute and the Macaw Recovery Network, both located in Costa Rica. The team also met with staff at the Cincinnati Zoo, Zoo Knoxville, and the Indianapolis Zoo

Conservation Tales - 2022 Central America Series

The Conservation Tales project is finishing work on two new books for this series of children's books. The books will feature Sloths and Macaws, and will make up the new "Central America Series." The set will be published in May 2022. Conservation Tales is an interdisciplinary team of students and faculty who work with a variety of external partners to create children's books about wildlife conservation and authentic science practices. In 2022, our external partners include The Sloth Institute and the Macaw Recovery Network, both located in Costa Rica. The team also met with staff at the Cincinnati Zoo, Zoo Knoxville, and the Indianapolis Zoo

Accuracy in Diagnosis of Celiac Disease Without Biopsies in Clinical Practice

The guidelines of the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition allow for diagnosis of celiac disease without biopsies in children with symptoms and levels of immunoglobulin A against tissue-transglutaminase (TGA-IgA) 10-fold or more the upper limit of normal (ULN), confirmed by detection of endomysium antibodies (EMA) and positivity for HLA-DQ2/DQ8. We performed a large, international prospective study to validate this approach